VET Cell Tech sp. z o.o.

Research and experimental development in natural sciences and engineering

KRS: NIP: REGON:

Overview

Status
Active
Registry date
2023-03-21
Share capital
63,250.00 PLN
Activity description

Vet Cell Tech is a veterinary biotech company from Poland that develops innovative stem cell-based therapies for dogs and cats. They utilize a proprietary stem cell technology platform to create effective treatments for common diseases in companion animals. The company focuses on ensuring high safety profiles and cost-effectiveness in their products.

Registered address
ul. Profesora Michała Bobrzyńskiego 14, 30-348 Kraków, Poland
Email
Phone
Electronic delivery address
AE:PL-87122-26961-BBEAS-19

Financials

Revenue history (in k)

Filing timeliness

2 of 3 financial statements were filed late (the longest delay 73 days for 2023).

  • 202513/07/2026
  • 202417/07/2025
  • 202326/09/2024
Filed on timeDelayFiling deadline

Data and insights are generated automatically from financial statements – they may contain errors and are neither a credit assessment nor business advice.

Statistics

How the company ranks by revenue within its industry, city, voivodeship and across Poland in 2025.

Top 30%
Top 27%
City · Kraków5,959 / 16,158
Top 37%
Voivodeship · Małopolskie11,411 / 27,734
Top 41%
Country · Poland124,593 / 297,266
Top 42%

Results vs industry

Revenue
This companyUSD 483.44kMedianUSD 153.26kAverageUSD 4.77m
Net profit
This companyUSD -519.51kMedianUSD -293.45AverageUSD 306.55k
Operating costs
This companyUSD 1.00mMedianUSD 188.47kAverageUSD 4.59m
Assets
This companyUSD 2.10mMedianUSD 281.58kAverageUSD 8.35m

Offer

  • Veterinary therapies
  • Cell products
  • Stem cell banks
  • iPSC cell lines

Websites

  • vetcelltech.comVet Cell Tech - innowacyjne produkty oparte na komórkach macierzystych dla psów i kotów.
    WordPress 7.1Yoast SEOApache

Authorized Representatives

Konrad Grzegorz Szczukiewicz age 37 – Management Board Member
Marcin Krzysztof Liwoch age 53 – Management Board Member
Marcin Marek Majka age 54 – President of the Management Board

Manner of representation

Each member of the management board is authorized to make declarations on behalf of the company independently.

Supervisory board

Artur Zaręba age 55 – Supervisory Board Member
Igor Rozbicki age 50 – Supervisory Board Member
Radosław Janus age 37 – Supervisory Board Member
Jolanta Kołodziejczyk age 54 – Supervisory Board Member
Karolina Kozłowska age 48 – Supervisory Board Member

Ownership

OwnerSharesShare valueStake
194$2,620.2115.336%
450$6,077.8035.5731%
188$2,539.1714.8617%
303$4,092.3823.9526%
Others
130$1,755.8110.2766%

Beneficial owners

Person

Bank accounts

Registered as a VAT taxpayer on 2023-04-12.

Debt

No entries in the National Debtors Register (KRZ).

Public aid

7 public aid cases recorded, with a total value of $2,177,505.

PurposeGross amount
De minimis aid (in accordance with Commission Regulation 2023/2831)
–
De minimis aid (in accordance with Commission Regulation 2023/2831)
–
Regional investment aid
–

European Funds

ProjectEU co-financing
Research into the use of cell therapy to treat urinary system dysfunction in companion animals (female dogs)
$52,722
Development of a globally innovative veterinary drug for chronic kidney disease in cats, based on allogeneic stem cells, and implementation of production under GMP pharmaceutical standards
$1.6M
Purchase of infrastructure for conducting R&D on cell cultures under sterile conditions to develop globally innovative veterinary cell therapies
$468.5K

Regulatory authorisations

AuthorityTypeStatus
BDO register entry Active

Competitors

Name
Bioceltix S.A.
Famicordtx S.A.
Human Biome S.A.
Animal Active sp. z o.o.
Forvite P.S.A.
Przychodnia Weterynaryjna Avi-Vet sp. z o.o.
Vaxican sp. z o.o.
Multiqure S.A.
Bioactive-Tech sp. z o.o.
Nanosanguis S.A.

Change history

DateEvent
2025-08-05Share capital increase
2025-08-05Switch to PKD 2025
2023-09-01Share capital increase
2023-03-21Entered in the register

FAQ

Last updated: 2026-10-19